LINK BETWEEN CATARACT SURGERY AND HIP FRACTURES. A recent study was conducted to determine the association of cataract surgery with subsequent fracture risk in 1,113,640 U.S. Medicare beneficiaries aged 65 and older. Of these patients, 410,809 received cataract surgery and 13,976 patients sustained a hip fracture. The final results showed patients who had cataract surgery had lower odds of hip fracture within one year after surgery compared with patients who had not undergone cataract surgery.
GINKGO BILOBA IMPROVES VISUAL FUNCTION. A retrospective analysis was performed to evaluate the effect of Ginkgo biloba extract and anthocyanins on visual function in patients with normal tension glaucoma. After anthocyanin treatment, the mean best-corrected visual acuity for all eyes improved from 0.16 to 0.11 logMAR units and Humphrey Visual Field mean deviation improved from -6.44 to -5.34. After Ginkgo biloba extract treatment, Humphrey Visual Field mean deviation improved from -5.25 to -4.31. The study concluded that anthocyanins and Ginkgo biloba extract may be helpful in individuals with normal tension glaucoma.
ANXIETY AND DEPRESSION IN GLAUCOMA PATIENTS. Anxiety and depression in 408 patients with glaucoma were evaluated using the hospital anxiety and depression scale (HADS) questionnaire, which consists of two subscales, representing HADS-anxiety (HADS-A) and HADS-depression (HADS-D). The study discovered that a younger age was found to be a risk factor for anxiety, while an older age and increasing glaucoma severity were risk factors for depression in patients with glaucoma.
BEVACIZUMAB SHOWN EFFECTIVE IN CRVO. A prospective, double-masked study randomized 60 eyes with macular edema secondary to central retinal vein occlusion (CRVO) to receive bevacizumab or sham injection every six weeks for six months. At week 24, 60% of treated eyes gained ≥15 letters compared with 20% in the sham group. Mean decrease in central retinal thickness was greater in treated eyes, and there was no residual edema in 86.7% of treated eyes compared with 20% in the sham group. It was concluded that intraocular injections of bevacizumab improve visual acuity and reduce macular edema significantly compared with sham.